Susan M. O'BRien

Susan M. O'BRien

Auto-generated profile, based on publicly available information

Susan M. O'BRien

UC Irvine, Chao Family Comprehensive Cancer Center, Irvine, California

Research Focus & Metrics

Academic Career Length

34Years (1993-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 September 2019 in American Journal of Hematology
Verified
Journal Article
Open access
PDF file
TMTalha Munir
Talha Munir
JBJennifer R. Brown
Jennifer R. Brown
SOSusan O'BRien
Susan O'BRien
JBJacqueline C. Barrientos
Jacqueline C. Barrientos
PBPaul M. Barr
Paul M. Barr
JWJennifer A. Woyach
Jennifer A. Woyach
Ibrutinib, a once‐daily oral inhibitor of Bruton's tyrosine kinase, is approved in the United States and Europe for treatment of patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The phase 3 RESONATE study showed improved efficacy of single‐agent ibrutinib over ofatumumab in patients with relapsed/refractory CLL/SLL, including those with high‐risk features. Here we report the final analysis from RESONATE with median follow‐up on study of 65.3 months (range, 0.3‐71.6) in the ibrutinib arm. Median progression‐free survival (PFS) remained significantly longer for patients randomized to ibrutinib vs ofatumumab (44.1 vs 8.1 months; hazard ratio [HR]: 0.148; 95% confidence interval [CI]: 0.113‐0.196; P˂.001). The PFS benefit with ibrutinib vs ofatumumab was preserved in the genomic high‐risk population with del(17p), TP53 mutation, del(11q), and/or unmutated IGHV status (median PFS 44.1 vs 8.0 months; HR: 0.110; 95% CI: 0.080‐0.152), which represented 82% of patients. Overall response rate with ibrutinib was 91% (complete response/complete response with incomplete bone marrow recovery, 11%). Overall survival, censored for crossover, was better with ibrutinib than ofatumumab (HR: 0.639; 95% CI: 0.418‐0.975). With up to 71 months (median 41 months) of ibrutinib therapy, the safety profile remained consistent with prior reports; cumulatively, all‐grade (grade ≥3) hypertension and atrial fibrillation occurred in 21% (9%) and 12% (6%) of patients, respectively. Only 16% discontinued ibrutinib because of adverse events (AEs). These long‐term results confirm the robust efficacy of ibrutinib in relapsed/refractory CLL/SLL irrespective of high‐risk clinical or genomic features, with no unexpected AEs. This trial is registered at www.clinicaltrials.gov (NCT01578707).

26 April 2018 in Blood
Verified
Journal Article
Open access
PDF file
SOSusan O’bRien
Susan O’bRien
RFRichard R. Furman
Richard R. Furman
SCSteven Coutre
Steven Coutre
IFIan W. Flinn
Ian W. Flinn
JBJan A. Burger
Jan A. Burger
JBJohn C. Byrd
John C. Byrd
Key Points: Our 5-year experience shows sustained single-agent efficacy of ibrutinib in CLL patients, with complete response rates increasing over time. Long-term ibrutinib was well tolerated with no new safety signals; rates of grade ≥3 cytopenias decreased with continued therapy.

1 October 2016 in The Lancet Oncology
Verified
Journal Article
Closed access
SOSusan O'BRien
Susan O'BRien
JJJeffrey A Jones
Jeffrey A Jones
SCSteven E Coutre
Steven E Coutre
AMAnthony R Mato
Anthony R Mato
PHPeter Hillmen
Peter Hillmen
SSStephan Stilgenbauer
Stephan Stilgenbauer

17 December 2015 in Blood
Verified
Journal Article
Open access
PDF file
SOSusan M. O'Brien
Susan M. O'Brien
NLNicole Lamanna
Nicole Lamanna
TKThomas J. Kipps
Thomas J. Kipps
IFIan Flinn
Ian Flinn
AZAndrew D. Zelenetz
Andrew D. Zelenetz
SCSteven E. Coutre
Steven E. Coutre
Key Points: In 64 older patients with untreated CLL or small lymphocytic leukemia, treatment with idelalisib plus rituximab was generally well tolerated. The combination produced a very high response rate (97%), including 19% complete remission.

1 August 2016 in Cancer
Verified
Journal Article
Open access
PDF file
KSKoji Sasaki
Koji Sasaki
EJElias Jabbour
Elias Jabbour
FRFarhad Ravandi
Farhad Ravandi
Nicholas J. ShortNicholas J. Short
Nicholas J. Short
DTDeborah A. Thomas
Deborah A. Thomas
HKHagop M. Kantarjian
Hagop M. Kantarjian
BACKGROUND: The clinical efficacy of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (HCVAD) plus ponatinib has not been compared with that of HCVAD plus dasatinib in patients with Philadelphia chromosome‐positive acute lymphoblastic leukemia (Ph+ ALL) in a randomized clinical trial.METHODS: The authors analyzed 110 patients with newly diagnosed Ph+ ALL who were enrolled in 2 consecutive, prospective, phase 2 clinical trials of frontline HCVAD with either dasatinib (63 patients) or ponatinib (47 patients). Propensity score analysis with 1:1 matching with the nearest neighbor matching method and inverse probability of treatment weighting (IPTW) analysis based on the propensity scores were performed to assess response rates, event‐free survival (EFS), and overall survival (OS) between the cohorts.RESULTS: Propensity score matching identified 41 patients in each cohort. With propensity score matching, the 3‐year EFS rates for patients treated with HCVAD plus ponatinib and HCVAD plus dasatinib were 69% and 46%, respectively (P =.04), and the 3‐year OS rates were 83% and 56%, respectively (P =.03). IPTW analysis using prematching cohorts demonstrated that patients treated with HCVAD plus ponatinib had significantly higher rates of minimal residual disease negativity by flow cytometry on day 21, complete cytogenetic response at complete response, major molecular response at complete response and at 3 months, and complete molecular response at 3 months. IPTW confirmed that treatment with HCVAD plus ponatinib was associated with longer EFS (P =.003) and OS (P =.001) compared with treatment with HCVAD plus dasatinib.CONCLUSIONS: The clinical outcome of patients treated with HCVAD plus ponatinib appears to be superior to that of patients treated with HCVAD plus dasatinib among individuals with Ph+ ALL. Cancer 2016;122:3650‐6. © 2016 American Cancer Society.

25 July 2017 in Cancer
Verified
Journal Article
Open access
PDF file
PJPreetesh Jain
Preetesh Jain
HKHagop M. Kantarjian
Hagop M. Kantarjian
AGAhmad Ghorab
Ahmad Ghorab
KSKoji Sasaki
Koji Sasaki
EJElias J. Jabbour
Elias J. Jabbour
JCJorge Cortes
Jorge Cortes
BACKGROUND: Outcomes in patients with chronic myeloid leukemia in blast phase (CML‐BP) are historically dismal. Herein, the authors sought to analyze the characteristics, prognostic factors, and survival outcomes in patients with CML‐BP in the tyrosine kinase inhibitor (TKI) era.METHODS: A total of 477 patients with CML‐BP were treated with a TKI at some point during the course of their CML. Cox proportional hazard models identified characteristics that were predictive of survival. Overall survival and failure‐free survival were assessed. Optimal cutoff points for specific parameters were identified using classification and regression tree (CART) analysis.RESULTS: The median age of the patients was 53 years (range, 16‐84 years) and 64% were male. Approximately 80% of patients initially were diagnosed in the chronic phase of CML at a median of 41 months (range, 0.7‐298 months) before transformation to CML‐BP. De novo CML‐BP occurred in 71 patients. Approximately 72% of patients received TKI therapy before CML‐BP. The initial therapy for CML‐BP included a TKI alone (35%), a TKI with chemotherapy (46%), and non‐TKI therapies (19%). The median overall survival was 12 months and the median failure‐free survival was 5 months. In multivariate analysis, myeloid immunophenotype, prior TKI, age ≥58 years, lactate dehydrogenase level ≥1227 IU/L, platelet count < 102 K/μL, no history of stem cell transplantation, transition to BP from chronic phase/accelerated phase, and the presence of chromosome 15 aberrations predicted for a significantly increased risk of death. Achievement of major hematologic response and/or complete cytogenetic response to first‐line treatment was found to be predictive of better survival. The combination of a TKI with intensive chemotherapy followed by stem cell transplantation appeared to confer the best outcome.CONCLUSIONS: Patients with CML‐BP continue to pose a therapeutic challenge, have dismal outcomes, and require newer treatment approaches. Cancer 2017;123:4391‐402. © 2017 American Cancer Society.